
Gilead’s Epclusa (sofosbuvir and velpatasvir) has been awarded new marketing approval from the FDA in the treatment of hepatitis C …

The COVID-19 pandemic will affect European launches of drugs for a host of diseases including HIV, cancer and sickle cell …

AstraZeneca has confirmed that its PARP inhibitor Lynparza (olaparib) has been awarded orphan drug designation in Japan for the maintenance …

Novartis has revealed that its gene therapy Zolgensma (onasemnogene abeparvovec) has secured approval from Japan’s Ministry of Health, Labour and …

Total global spending on medicines is set to break $1.1 trillion by 2024, a new report released by IQVIA has …

It is now known that around 100 of the known cases of the COVID-19 coronavirus can be traced to an …

The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles on the road to regulatory …

NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng …

Authored by Dan Boot, Head of Digital Innovation at RB Health.Around the world, populations are aging. According to the World …

Novo Nordisk has moved to temporarily shut down two of its Phase 3 and one of its Phase 2 clinical …

AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …

The race to develop a vaccine against the ongoing outbreak of novel coronavirus has stepped up with the news that …

Genmab has announced the establishment of the new position of Chief Operating Officer at the company, and has furthermore named …

President Trump has attracted criticism from all sides over his response to the novel coronavirus outbreak; after repeatedly downplaying the …

NHS England is set to fund the availability of pre-exposure prophylaxis (PrEP) for the prevention of HIV for local authorities …